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Key Points 
• Autosomal recessive loss-of-function mutations in G6b-B (MPIG6B) cause 
congenital macrothrombocytopenia with focal myelofibrosis (cMTFM). 
• G6b-B has orthologous physiological functions in human and mice regulating 
megakaryocyte and platelet production and function. 
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Abstract  
Unlike primary myelofibrosis (PMF) in adults, myelofibrosis in children is rare. Congenital 
(inherited) forms of myelofibrosis (cMF) have been described, but the underlying genetic 
mechanisms remain elusive.  Here we describe 4 families with autosomal recessive inherited 
macrothrombocytopenia with focal myelofibrosis due to germline loss-of-function mutations in 
the megakaryocyte-specific immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing 
receptor G6b-B (G6b, C6orf25 or MPIG6B).  Patients presented with a mild-to-moderate 
bleeding diathesis, macrothrombocytopenia, anemia, leukocytosis and atypical 
megakaryocytes associated with a distinctive, focal, perimegakaryocytic pattern of bone 
marrow fibrosis.  In addition to identifying the responsible gene, the description of G6b-B as 
the mutated protein potentially implicates aberrant G6b-B megakaryocytic signaling and 
activation in the pathogenesis of myelofibrosis.  Targeted insertion of human G6b in mice 
rescued the knockout phenotype and a copy number effect of human G6b-B expression was 
observed.  Homozygous knockin mice expressed 25% of human G6b-B and exhibited a 
marginal reduction in platelet count and mild alterations in platelet function; these phenotypes 
were more severe in heterozygous mice that expressed only 12% of human G6b-B.  This study 
establishes G6b-B as a critical regulator of platelet homeostasis in humans and mice.  In 
addition, the humanized G6b mouse will provide an invaluable tool for further investigating the 
physiological functions of human G6b-B as well as testing the efficacy of drugs targeting this 
receptor. 
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Introduction 
Myelofibrosis in children is rare, and,  in children, is most commonly seen in association with 
acute megakaryoblastic leukemia.1  Other causes include acute lymphoblastic leukemia 
(ALL),2 Hodgkin lymphoma3, severe vitamin D or C deficiency,4,5 6 renal osteodystrophy7, 
osteopetrosis, hyperparathyroidism8, autoimmunity,9-11 and tuberculosis.12  The clinical, 
histologic and molecular features of pediatric myelofibrosis differ from primary myelofibrosis 
(PMF) in adults, which is typically due to somatic gain-of-function mutations in tyrosine kinase 
(TK) signaling pathways, including JAK2 V617F (50%), MPL W515K/L (5-10%) or CALR 
(35%);13,14  TK mutations are not typically present in pediatric myelofibrosis, particularly not in 
young children.15,1,16  Children with myelofibrosis have a heterogeneous phenotype with 
variable outcomes.  Some patients have spontaneous resolution,17,18 while others have an 
aggressive clinical course with progressive, sometimes fatal disease cured only by 
hematopoietic stem cell transplantation (HSCT)15,19-21. 
Congenital or inherited forms of myelofibrosis (cMF) are exceedingly rare with fewer than 50 
cases reported.15,18-26  Many cases occur in consanguineous families,15,19,25 suggesting that 
cMF can be inherited as a autosomal recessive Mendelian trait.  Genetic lesions have been 
identified in only a small minority of cases.  In some, concurrent single lineage cytopenias have 
been described.  For example, homozygous germline mutations in VPS45 cause neutropenia, 
neutrophil dysfunction, bone marrow (BM) fibrosis, progressive marrow failure and 
organomegaly.27,28  In some patients, fibrosis coexists with an intrinsic platelet disorder, such 
as gray platelet syndrome (GPS) to gain-of-function mutations in the Growth Factor Inhibitor 
1B (GFI1B) gene29 or biallelic mutations in neurobeachin-like 2 (NBEAL2).30-32  These 
phenotypes are quite distinct from most patients with cMF. 
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Here we describe the clinical phenotype, distinctive histological features and biallelic loss-of-
function mutations in the megakaryocyte-specific immunoreceptor tyrosine-based inhibitor 
motif (ITIM)-containing receptor G6b-B (C6orf25 or MIPG6B, referred to as G6b) in four 
families with a clinically distinctive form of cMF associated with macrothrombocytopenia and 
focal myelofibrosis (cMTFM).  These phenotypes closely resemble those reported in G6b 
knockout (KO) and loss-of-function mice (Geer et al. co-submitted).33 A humanized G6b 
transgenic knockin (KI) mouse model establishes that human and mouse G6b-B perform 
orthologous  functions.  Mice homozygous for human G6b (G6bhu/hu) exhibit a mild platelet 
disorder attributed to reduced human G6b-B expression.  Reduced G6b-B expression in 
G6bhu/hu and heterozygous (G6bhu/-) mice also revealed novel regulatory roles of G6b-B with 
respect to immunoreceptor tyrosine-based activation motif (ITAM) and hemi-ITAM receptor 
signaling. 
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Materials and Methods 
Patients 
Families 1-3 consented to the Pediatric Myelodysplastic Syndrome and Bone Marrow Failure 
Registry (Boston Children’s Hospital, Protocol #10-02-0057).  Family 4 was consented to the 
Biomedical Research Centres/Units Inherited Diseases Genetic Evaluation-Bleeding and 
Platelet Disorders (BRIDGE-BPD) study (UK REC10/H0304/6).  All studies were conducted 
according to the Declaration of Helsinki.  
Hematological characterization and sample preparation 
Complete blood counts (CBC) and BM aspirates and biopsies were obtained on all clinically 
affected individuals; CBCs were obtained on other family members.  Whole blood or BM 
mononuclear cell DNA was extracted using the Qiagen Puregene Blood Kit (Qiagen, 
Germantown, MD).  BM aspirate and biopsy histology were prepared using standard clinical 
procedures.  Images were obtained with an Olympus BX43 microscope and DP25 digital 
camera and acquired with the Olympus CellSens Entry Imaging Software. 
Flow cytometry, immunohistochemistry, and immunoblotting 
Flow cytometry was performed on an BD Accuri C6 flow cytometer using methods and 
antibodies described in the Supplemental Methods. Immunohistochemical (IHC) staining for 
CD61 was done on Bouin’s-fixed, paraffin-embedded tissue sections using the Ventana 
Discovery XT automated platform.  A similar, custom automated IHC method was developed 
using a monoclonal antibody directed against the N-terminal ectodomain of G6b-B.33 Western 
blotting and immunoprecipitations were performed as previously described.34 
Linkage and sequencing analysis 
Affymetrix 6.0 SNP genotyping (QuintilesIMS, Research Triangle Park, NC) was performed on 
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members of the index family (Family 1) and analyzed using a custom platform (Variant 
Explorer, K.S.-A. and K.M., unpublished).  Whole exome sequencing (WES) was performed in 
patients and immediate family members of Family 1 using the Illumina TrueSeq enrichment 
protocol.  Families 2 and 3 were sequenced using the Agilent SureSelect exome capture 
enrichment protocol.  Sequencing was performed on an Illumina Hiseq 2000/2500 with 100bp 
paired-end sequencing with an average depth of 40-200x (Macrogen, Rockville, MD).  FASTq 
sequences were processed and analyzed using the WuXi/NextCode platform (Cambridge, 
MA).  For individual 4-II-3, DNA library preparation, sequencing, variant calling and variant 
filtering were performed as described previously.35  Confirmatory Sanger sequencing was 
carried out on all patients and available family members as described in the Supplementary 
Methods.  
Mouse models 
Humanized G6b KI mice were generated as outlined in Figure S1 and supplementary material 
(Taconic Biosciences, Cologne, Germany).  G6b constitutive KO (G6b-/-) mouse models were 
generated as previously described.33  All mice were on a C57BL/6 background and procedures 
were undertaken with UK Home Office approval, in accordance with the Animals (Scientific 
Procedures) Act of 1986. Detailed descriptions of all other methods can be found in 
Supplementary Methods. 
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Results  
Clinical and pathological characteristics 
We studied four consanguineous Arab families presenting with macrothrombocytopenia, 
anemia and myelofibrosis.  Family 1, from the United Arab Emirates (UAE), had three affected 
male siblings born to first cousin parents.  Affected individuals (Figure 1A and Table 1, 1-III-1, 
1-III-5, and 1-III-6) had macrothrombocytopenia with variably reduced platelet granularity, and 
microcytic anemia.  BM studies revealed clusters of atypical megakaryocytes with reticulin 
fibrosis that was most pronounced in proximity to the megakaryocytes.  Affected children had 
mild to moderate bleeding symptoms and required frequent platelet and occasional red cell 
transfusions; each affecte individual shared a homozygous human leukocyte antigen (HLA) 
haplotype and had congenital adrenal hyperplasia (CAH) due to 21-hydroxylase (CYP21A2) 
deficiency.  The children had three apparently unaffected cousins born to siblings of their 
parents.  One female cousin had CAH and shared the same homozygous HLA type as her 
affected cousins (Figure 1A and Table 1, 1-III-9,).  She was not thrombocytopenic and had 
only rare large platelets on her peripheral blood smear (Figure 2C).  While being evaluated as 
a transplant donor for her cousins, she underwent multiple BM studies, the first of which 
showed several lymphoid aggregates with associated reticulin, but normal megakaryocytes.  
Follow-up BM studies (Figure 2F, I) were normal.  Given the lack of a sibling, unrelated or cord 
blood donor, persistent transfusion dependency and lack of response to immunomodulatory 
agents, patients 1-III-5 and 1-III-6 underwent successful matched related HSCTs with 1-III-9 
serving as the donor.  Both patients engrafted and are doing well following HSCT.  The 
proband in this family, 1-III-1, was transplanted using a haploidentical approach from his 
mother, and eventually succumbed to transplant-related complications.15 
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Family 2 (Figure 1) is from Saudi Arabia.  The proband (2-II-6), whose parents are first 
cousins, had transient thrombocytopenia at birth.  Thrombocytopenia recurred at 6-months of 
life and was associated with severe microcytic anemia unresponsive to iron therapy.  BM 
studies performed elsewhere at age 2-years were reported to be normal.  Severe 
thrombocytopenia and anemia persisted despite several courses of intravenous 
immunoglobulin and steroids.  A BM at age 3-years showed a hypercellular marrow with 
increased lymphocytes, and clustering of atypical megakaryocytes with focal reticulin fibrosis.  
The patient’s older brother (2-II-5) was found to be an HLA identical match, but was ineligible 
as a donor due to moderate macrothrombocytopenia.  BM studies are not available for this 
individual, though he is presumed to be clinically affected.  Given the lack of a suitable donor 
and their mild phenotype requiring only occasional platelet transfusions, both children continue 
to be monitored. 
The proband in Family 3 (Figure 1A, 3-II-4) is the daughter of first cousin consanguineous 
parents from the UAE.  She presented at 15-months of age with leukocytosis, severe 
microcytic anemia and macrothrombocytopenia.  Her clinical features were strikingly similar to 
the affected children in Family 1.  Her BM showed a mildly hypercellular marrow for her age 
with a relative myeloid hyperplasia and clusters of atypical megakaryocytes with associated 
reticulin fibrosis.  Although Family 1 and Family 3 are not known to be related, 3-II-4 also has 
CAH and shares the same homozygous HLA type and CYP21A2 mutation as Family 1.  She is 
currently being followed without therapeutic intervention. JAK2, MPL and CALR mutation 
analysis  was negative in patients from Fimilies 1-3 (Table 1). 
The fourth family included an affected male and female sibling pair with 
macrothrombocytopenia, increased BM megakaryocytes, and grade II BM myelofibrosis 
 
 
 
 
 
 
11 
(Figure 1A, 4-II-2, 4-II-3).  These children and an unaffected brother were born to first cousins 
of Arab descent.  The affected boy (4-II-2) had a more severe phenotype, including anemia 
with Howell-Jolly bodies, elevated fetal hemoglobin, dyserythropoiesis and 
dysmegakaryopoiesis.  Platelet surface expression of GPIb, IIb, 2 and GPIV were all 
unaltered, and there was a minor reduction in aggregation to ADP (data not shown). 
A detailed description of each case is included in the Supplemental Data. 
 
Linkage, mutational and protein expression analyses 
We performed Affymetrix SNP 6.0 genotyping on peripheral blood DNA from 10 individuals 
from Family 1 and assessed shared regions of homozygosity by descent in 1-III-5 and 1-III-6; 
1-III-9 was regarded as having an ambiguous phenotype. The major histocompatibility locus 
(MHC) on chromosome 6p, which, although not statistically significant, showed the strongest 
linkage (LOD=2.01, Figure 1B).  We focused on this region, because affected individuals in 
Family 1 and 3 had an identical homozygous HLA type and congenital adrenal hyperplasia 
(CAH) due to the identical CYP21A2 mutation (Table 1).  Furthermore, both affected 
individuals in Family 2 had a different, but homozygous, HLA haplotype; the CYP21A2 and 
HLA loci are located at 6p21.33 and 6p21.32-6p22.1, respectively (Figure 1B). 
We performed WES on nuclear families 1-3, and on individual 4-II-3 and interrogated the 
results for genes in which unambiguously affected members of each family carried a 
homozygous rare variant (allele frequency <0.005) within the candidate disease interval 
predicted to be functionally deleterious.  The only gene meeting these criteria was the 
megakaryocyte and platelet-specific receptor G6b (MPIG6B, C6orf25, referred to as G6b-B or 
G6b). 
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G6b-B is a transmembrane receptor expressed on the surface of platelets and 
megakaryocytes.33,36-38  G6b-B has one extracellular immunoglobulin-like domain, a single 
transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM) and 
immunoreceptor tyrosine-based switch motif (ITSM) in its cytoplasmic tail.  Tyrosine 
phosphorylation of the ITIM and ITSM provides a docking site for the SRC homology 2 (SH2) 
domain-containing tyrosine phosphatases SHP1 (PTPN6) and SHP2 (PTPN11), which 
mediate downstream signalling.39,40  Murine KO and loss-of-function models of G6b result in a 
phenotype very similar to the patients, including macrothrombocytopenia, abnormal platelet 
function and the perimegakaryocytic pattern of bone marrow fibrosis present in patients (Geer 
at al. co-submitted).33  BM-derived mouse G6b-B-deficient megakaryocytes develop and 
proliferate normally in vitro, but failed to form highly branched proplatelets, suggesting that 
G6b-B regulates proplatelet formation, correlating with reduced platelet production.33  
Families 1 and 3 shared the same variant, a two base pair duplication bridging a splice donor 
site, NM_138272.2 c.61_61+1dup (p.?), and Family 2 had a unique homozygous frameshift 
mutation, c.149dup (p.Ala52GlyfsX128, Figure 1B).  These variants segregated with the 
phenotype in families 2 and 3; however, in family 1, individual 1-III-9, who had served as the 
HSCT donor for her cousins, genotyped as a homozygous mutant, despite having no overt 
clinical features of the disease other than rare giant platelets (Figure 2C).  In Family 4, we 
found a novel apparently homozygous missense variant c.469G>A (p.Gly157Arg, Figure 1B).  
The variant was also homozygous in the affected brother.  
Residues 143-163 encode the predicted transmembrane domain of G6b-B, and substituting a 
glycine with arginine would likely destabilize insertion of the receptor into the membrane.  
Expression of the p.Gly157Arg mutant protein was tested using transiently transfected DT40 
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cells.  Introduction of the mutation caused a significant reduction in total G6b-B protein 
expression (Figure 1C), and surface expression was reduced by 84% by flow cytometry 
(Figures 1D, E).  A comparable reduction in expression was also observed in transiently 
transfected Chinese hamster ovary (CHO) cell line (data not shown). These data suggest that 
this rare missense variant is functionally significant. 
To further validate G6b variants as disease-causing, we evaluated G6b-B expression in BM 
biopsy specimens from affected patients and control samples by IHC using a monoclonal 
antibody specific to the ectodomain.  G6b-B was strongly and selectively expressed in 
megakaryocytes and platelets of control BM samples, but completely absent in 
megakaryocytes and platelets of the genotypically affected individuals from families 1-3 (Figure 
2J-2O).  BM biopsy samples were not available for patient 4-II-2 or 4-II-3 with the p.Gly157Arg 
mutation.  Thus, in combination with the complementary phenotype observed in G6b-/- mice,33 
the thrombocytopenia and BM myelofibrosis found in these patients is almost certainly due to 
reduced or absent expression of G6b-B.  
 
Expression of human G6b-B in G6bhu/hu mice 
To confirm that human and mouse G6b-B are orthologous, we generated a humanized G6b 
mouse model in which mouse G6b was replaced with its human counterpart (Figure S1 and 
Supplemental Methods).  Mice were born at expected Mendelian frequencies from 
heterozygous (G6bhu/+) breeding pairs (Table S1), and G6bhu/hu mice were healthy, fertile and 
survived >25 weeks without any overt developmental or growth anomalies.  Expression of 
human and mouse G6b-B was verified by flow cytometry (Figure S2) and western blotting 
(Figure 3A).  Expression of the human G6b-A splice isoform, which lacks the ITIM and ITSM, 
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was also demonstrated using an isoform-specific antibody (Figure 3Ai, iv).  Both human 
isoforms were only expressed at 25% of normal human platelet levels.  The ratio of 
glycosylated (32 kDa) to unglycosylated (28 kDa) human G6b-B and -A was reduced from 3:2 
in human platelets to 2:3 in G6bhu/hu platelets (Figure 3B).   
The ability of human G6b-B to bind mouse Shp1 and Shp2 was also investigated in G6bhu/hu 
platelets (Figure 3C).  Similar amounts of human and mouse Shp1 and Shp2 co-
immunoprecipitated (co-IP’d) with human G6b-B from human and G6bhu/hu platelets under 
resting conditions (Figure 3Cii).  However, less Shp1 co-IP’d with human G6b-B from G6bhu/hu 
platelets compared with human platelets following collagen-stimulation, most likely reflecting 
differences in expression levels of Shp1 and Shp2 in human and mouse platelets (Figure 
S3).41,42  In contrast, comparable amounts of Shp2 co-IP’d with human G6b-B from collagen-
stimulated human and G6bhu/hu platelets. 
 
Human G6b-B functionally replaces mouse G6b-B 
Reduced human G6b-B expression resulted in an 21% reduction in platelet count and a 
marginal increase in platelet volume in G6bhu/hu mice (Table 2, Figure S4).  In contrast, 
complete ablation of G6b resulted in a >80% reduction in platelet count and >30% increase in 
platelet volume (Table 2), demonstrating that human G6b-B rescues the KO phenotype.  
Altered blood cell counts in G6b KO mice were independent of age (Figure S5).  Histological 
sections of spleens and femurs also demonstrated that expression of human G6b rescues the 
perimegakaryocytic pattern of bone marrow fibrosis previously identified in G6b KO mice 
(Figure S6).33  All other hematological parameters were normal in G6bhu/hu mice (Table 2).  
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Blood counts were normal in G6b+/hu and G6b+/- mice (Table 2).33  Platelet surface levels of 
GPVI, CLEC-2, 2, IIb and GPIb were normal in platelets from G6bhu/hu mice (Figure S7). 
 
Reduced human G6b-B expression causes minor alterations in platelet function 
G6bhu/hu platelets provide a unique model to investigate the physiological consequence of 
reduced human G6b-B levels in platelets, without altered expression of other receptors 
identified in G6b-/- mice.33  No significant defects were observed in IIb3-mediated adhesion 
and spreading of G6bhu/hu platelets on fibrinogen, in the presence or absence of thrombin 
(Figure S8).  Consistent with these findings, outside-in IIb3 signaling was comparable 
between WT and G6bhu/hu platelets (Figure S9).  Bands corresponding to tyrosine 
phosphorylated mouse (45 kDa) and human (28-34 kDa doublet) G6b-B were observed in 
fibrinogen-adhered WT and G6bhu/hu platelets, respectively.  As G6bhu/hu mice do not express 
mouse G6b-B (Figure 3), the tyrosine phosphorylated band at 45 kDa is due to the presence of 
other co-migrating phosphorylated proteins.  
We next investigated (hemi)-ITAM receptor-mediated functional responses.  Unexpectedly, 
platelet aggregation was marginally reduced in response to low and intermediate 
concentrations (1-10 g/ml) of the GPVI-specific agonist collagen-related peptide (CRP) 
(Figure 4A).  In contrast, CLEC-2-mediated platelet aggregation was marginally increased at 6 
g/ml anti-CLEC-2 antibody (Figure 4A).  Platelet aggregation to thrombin, collagen, ADP and 
the TxA2 analogue U46619 were normal (Figure S10).  ATP secretion from dense granules 
was normal to all agonists tested (Figure 4A and S10), except for a minor increase at an 
intermediate dose of collagen.  These findings reveal minor alternations in platelet functional 
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responses due to reduced human G6b-B expression that are likely of no physiological 
consequence. 
 
Altered G6bhu/hu platelet function does not affect thrombus formation or hemostasis 
We further investigated G6bhu/hu platelet functional responses under physiological flow 
conditions on different thrombogenic surfaces.  Platelet adhesion and thrombus formation were 
quantified by flowing anti-coagulated blood over: (1) collagen; (2) von Willebrand Factor-
binding protein (vWF-BP) and laminin; and (3) vWF-BP, laminin and the CLEC-2 agonist 
rhodocytin, for 3.5 minutes at 1,000 s-1.  Surface area coverage and morphological scores 
were used as measures of platelet adhesion and thrombus formation (Figure S11).  
Regression analysis of a cohort of WT mice (n=19) did not indicate that the 21% reduction in 
platelet counts in G6bhu/hu mice will affect any of the measured parameters (Figure S12)  The 
total surface area covered by G6bhu/hu platelets on collagen was unaltered compared with WT 
platelets (Figure 4B).  However, multilayer thrombus formation and contraction were both 
significantly increased, despite a minor reduction in IIb3 activation and normal -granule 
release, measured by immunostaining with JON/A and P-selectin antibodies, respectively 
(Figure 4B).  Altered thrombus morphology of G6bhu/hu platelets is most likely a reflection of the 
increased proportion of phosphatidylserine (PS)-positive procoagulant platelets, measured by 
Annexin V staining (Figure 4B). 
No difference in adhesion or platelet activation were observed when anti-coagulated blood 
from WT and G6bhu/hu mice was flowed over vWF-BP and laminin, or vWF-BP, laminin and 
rhodocytin (Figure S13).  Although some minor alterations in G6bhu/hu platelet activation were 
identified using this assay, expression of human G6b-B rescued the severe defects observed 
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in G6b-/- platelets.  This rescue is likely due to a combination of increased platelet counts and 
normalized platelet reactivity.  Functional defects observed in G6bhu/hu platelets did not 
culminate in compromised hemostasis in mice, as assessed using the tail bleeding assay, 
whereas G6b-/- mice bled excessively, as previously reported (Figure 4C).33  
To determine the molecular basis of altered responses to CRP and anti-CLEC-2 antibody, we 
investigated tyrosine phosphorylation in WT and G6bhu/hu platelets.  The findings from 
aggregations studies were supported by a minor reduction in global tyrosine phosphorylation 
following CRP stimulation (Figure 5A).  A trend towards reduced SFK and Syk activities was 
identified, as measured by changes in autophosphorylation of Tyr418 and Tyr519/20 in the 
activation loops of SFKs and Syk, respectively, though this did not reach significance (Figure 
5A).  SFK-mediated phosphorylation of the ITAM-containing FcR -chain, which acts as a 
docking site for Syk to propagate signals downstream of GPVI, was also marginally reduced in 
CRP-stimulated G6bhu/hu platelets.  The opposite was observed in CLEC-2 activated platelets, 
in which global tyrosine phosphorylation, SFK and Syk activation were marginally increased in 
response to antibody-mediated cross-linking and activation of CLEC-2 (Figure 5B).  However, 
only Syk activation with 10 g/ml anti-CLEC-2 antibody was significantly increased. 
 
Further reduction in human G6b-B expression exacerbates platelet defects 
To further investigate the threshold of human G6b-B expression required to rescue the G6b-/- 
phenotype, we generated human G6b hemizygous mice (G6bhu/-) by crossing G6bhu/hu mice 
with G6b-/- mice (Figure 6A).  G6bhu/- mice expressed only 12% of human G6b-B and -A 
compared with human platelets, and no mouse G6b-B (Figure 6A and S14A, B).  These 
expression levels produced an even greater reduction in platelet counts (29%) and a 
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comparable increase in platelet volume (6-7%) compared with G6bhu/hu mice (Table 2).  This 
provides further evidence that human G6b-B dose dependently regulates platelet production.  
Surface receptor expression was normal in G6bhu/- platelets compared with WT platelets, 
except for CLEC-2, which was marginally reduced by 16% (Figure S14C).  Interestingly, 
platelet aggregation was further reduced in response to CRP and increased in response to 
antibody-mediated cross-linking of CLEC-2 (Figure 6B).  These findings demonstrate 
differential roles of G6b-B in regulating ITAM- and hemi-ITAM-containing receptor-mediated 
platelet activation at these expression levels.  No difference was observed upon activation of 
CLEC-2 using the snake toxin rhodocytin.  This likely reflects the tetravalent structure of 
rhodocytin that can elicit a more robust CLEC-2 activating signal, thus abrogating the mild 
phenotype observed with the bivalent anti-CLEC-2 antibody.   Thrombin-mediated aggregation 
of G6bhu/- platelets was normal and no significant defects in ATP secretion was observed for all 
agonists tested. 
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Discussion 
Here we have described four families with a distinct phenotype of macrothrombocytopenia, 
microcytic anemia, variable leukocytosis and histologically characteristic megakaryocytic 
clustering, dysplasia and focal reticulin fibrosis in the BM presenting at young age.  We 
attribute this to homozygous loss-of-function mutations in G6b, the gene encoding G6b-B, a 
megakaryocytic/platelet-specific ITIM-containing receptor.  While this work was in preparation, 
another consanguineous Arab family with a similar phenotype was described with a 
homozygous predicted null mutation in G6b.26  These data firmly support the conclusion that 
recessive loss-of-function mutations in G6b result in the phenotype that we comprehensively 
describe and term congenital macrothrombocytopenia with cMTFM.  All of the clinically 
affected patients have a phenotype strikingly similar to a null mutation,33 or mutations that 
abolish ITIM/ITSM signaling,(Geer et al. co-submitted) in the murine orthologue.  
Concomitantly, we have demonstrated that the G6b KO phenotype can be rescued upon 
expression of human G6b.  
One apparently clinically unaffected individual, 1-III-9, without thrombocytopenia or anemia at 
the time of her evaluation as a transplant donor, also shares the G6b-B mutation; she did not 
have thrombocytopenia, bleeding symptoms, leukocytosis, anemia, or atypical 
megakaryocytes associated with fibrosis, but did have rare large platelets.  She did have 
transient BM lymphoid aggregates that are unusual for such a young child; these might be 
indicators of a primary BM disorder, but could equally be due to her CAH or other causes.  
Thus, it is likely that even genotypically similar patients might have varying expressivity or 
penetrance of the phenotype due to other modifying factors, including age, environment, and 
genotypes at other loci.  Indeed, for example, patient 2-II-5 came to medical attention only 
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because of his more severely affected younger sibling, 2-II-6.  In addition to modifiers noted 
above, there are several possible explanations for the successful HSCT of the two siblings, 1-
III-5 and 1-III-6 from their cousin, 1-III-9, who shares the same homozygous mutant G6b 
genotype.  First, it is conceivable that the conditioning regimen alters the niche directly, which 
could impact the regulation of other components important in the regulation of megakaryocytic 
development, proplatelet and platelet formation.  Second, introduction of a new hematopoietic 
stem cell pool from the donor into the host with cMF could lead to immunological graft and host 
interactions between the stem cell compartment and the niche that could alter megakaryocytic 
development. 
The cMTFM phenotype underscores the importance of G6b-B signaling in normal 
megakaryocyte and platelet biology. Binding of Shp1 and Shp2 are essential for mediating 
signal transduced by G6b-B.  A mutant form of G6b-B that uncouples it from Shp1 and Shp2 
signaling phenocopies the G6b KO mouse model (Geer et al. co-submitted),33 and a tissue-
specific mouse model of combined Shp1 and Shp2 deficiency recapitulates multiple features of 
G6b KO animals,43 further indicating the essential nature of this signaling pathway to 
megakaryocyte function.  
The majority of reported patients with cMF have undergone HSCT as it was felt to be the only 
curative treatment optio.15 The histological resemblance to PMF in adults, which carries a risk 
of evolution to acute myeloid leukemia and a poor prognosis, may have encouraged providers 
to offer HSCT out of due caution, even in the absence of evidence for adverse outcomes when 
managed conservatively.  Indeed, in our series of 7 cases of patients with G6b mutations, 
three required HSCT for cytopenias, one was clinically unaffected, and three have been 
observed without ongoing clinical interventions.  The identification of a molecular therapeutic 
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target—Shp1- and Shp2-dependent signal transduction—now offers the potential to 
circumvent the G6b-B deficiency in cMTFM and insights into the pathogenesis of other forms 
of primary and secondary myelofibrosis. 
The humanized G6b mouse provided compelling evidence of the analogous functions of 
human and mouse G6b-B.  The mild platelet phenotype, suggests human G6b-B interacts with 
the same ligands and signals in a similar manner to mouse G6b-B.  Reduced binding of human 
G6b-B to mouse Shp1 is most likely a reflection of the relative stoichiometries and binding 
affinities of Shp1 and Shp2 in mouse platelets.  Mouse platelets contain 6-fold higher levels of 
Shp2 than Shp1, whereas human platelets contain 2-fold more Shp1 than Shp2 (Figure 
S3).41,42  In addition, the binding affinity of tandem SH2 domains of human Shp2 with 
phosphorylated-G6b-B-ITIM-ITSM peptide is 100-fold greater than the binding affinity of 
tandem SH2 domains of Shp1.44  However, differences in the proportions of human G6b-B 
bound Shp1 and Shp2 in mouse versus human platelets are not likely to underlie the platelet 
defects described the humanized G6b mouse, as mouse G6b-B is predicted to bind the same 
ratios of Shp1 and Shp2.  Thus, platelet defects are more likely due to reduced human G6b-B 
expression. 
Despite the significant reduction in human G6b-B in G6bhu/hu and G6bhu/- mice, both mouse 
models exhibited only mild platelet phenotypes.  A large proportion of G6b-B is therefore not 
essential for maintenance of platelet homeostasis.  MKs from G6b-/- mice were previously 
shown to develop normally in vitro, but with significantly diminished proplatelet production 
capacity.33  Reduced platelet production in G6bhu/hu and G6bhu/- mice could therefore have 
been as a consequence of aberrant proplatelet formation, arising from reduced G6b-B 
expression in MKs.  The dose dependent nature of the reduction in platelet counts in these 
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homozygous and heterozygous mice adds to the growing body of evidence of the vital role of 
G6b-B in regulating platelet production. 
The reduction in human G6b-B expression was predicted to lead to an increase in platelet 
reactivity to collagen.  Indeed, thrombus formation and contraction were significantly increased 
when whole blood was flowed over collagen, despite a marginal reduction in integrin IIb3 
activation.  This can be explained by an enhancement in PS exposure and increased 
procoagulant activity of G6bhu/hu platelets, which is dependent upon PLC2-mediated Ca2+ flux 
and phosphatidylinositol 3-kinase signaling,45 highlighting these as potential downstream 
targets of Shp1 and Shp2.  The dose-dependent reduction in aggregation of G6bhu/hu and 
G6bhu/- platelets to CRP was however, counter-intuitive, suggesting G6b-B may act as both a 
positive and negative regulator of GPVI signaling, depending upon expression levels.  The 
candidate target of G6b-B-associated Shp1 and Shp2 is Syk tyrosine kinase that we previously 
showed is hyper-activated in G6b-B-deficient platelets.33  Syk contains multiple regulatory 
tyrosine phosphorylation sites that Shp1 and Shp2 may differentially dephosphorylate, 
depending upon the expression level of G6b-B, leading to either positive or negative effects on 
Syk activity.46 
This study establishes that human and mouse G6b-B perform the same physiological 
functions, and that deletion and loss-of-function mutations in G6b-B lead to megakaryocytic 
and myelofibrotic disorders in both species.  Validation of these analogous functions is 
essential to progress with exploring the role of G6b-B in various pathological conditions in 
humans and as a novel therapeutic drug target.  The humanized G6b-B mouse model 
described here provides an invaluable tool for investigating the efficacy and therapeutic 
potential of agents targeting human G6b-B in various disease conditions, including 
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myeloproliferation and myelofibrosis, allowing for a greater understanding of the mechanism of 
action of these therapies. 
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Tables 
Table 1.  Clinical and laboratory characteristics, treatments and outcomes of patients with congenital myelofibrosis. 
 
not available (NA), not done (ND), congenital adrenal hyperplasia (CAH), hematopoietic stem cell transplant (HSCT) 
 
 
 
ID  Age Sex WBC HGB PLT MCV MPV 
Peripheral blood 
smear morphology 
Other clinical 
features JAK2 MPL CALR 
Therapy and 
response 
HLA   
A B C DRB1 DQB1 G6B genotype Outcome 
1-III-1 5 m M NA 6.0 20 66.0 NA microcytosis, 
anisopoikilocytosis, 
target cells, ovalocytes, 
large platelets 
CAH Neg ND ND no pre-HSCT 
therapy 
S/P 2 
haploidentical 
HSCT from 
mother 
11:01 
11:01 
41:01 
41:01 
07:01 
07:01 
08:04 
08:04 
03:01 
03:01 
c.61_61+1dup/ 
c.61_61+1dup 
Deceased from SCT complications, 
graft failure after 2nd HSCT, GI bleed, 
ARDS 
1-III-5 Birt
h 
M NA 6.9 16 NA NA anisopoikilocytosis, 
target cells, basophilic 
stippling, large platelets 
CAH Neg Neg Neg steroids, 
transient partial 
response but 
not sustained. 
Platelets 
declined with 
taper. 
MRD HSCT 
from 1-III-9 
11:01 
11:01 
41:01 
41:01 
07:01 
07:01 
08:04 
08:04 
03:01 
03:01 
c.61_61+1dup/ 
c.61_61+1dup 
6 years post-HSCT, engrafted, 
maturing trilineage hematopoiesis with 
no evidence of fibrosis. 
1-III-6 6 m M 13.79 8.7 19 68.0 NA microcytosis, 
anisopoikilocytosis, 
target cells, basophilic 
stippling, tear drops, 
frequent large platelets 
CAH Neg Neg Neg no pre-HSCT 
therapy. 
MRD HSCT 
from 1-III-9 
11:01 
11:01 
41:01 
41:01 
07:01 
07:01 
08:04 
08:04 
03:01 
03:01 
c.61_61+1dup/ 
c.61_61+1dup 
4 years post-HSCT.  Slow platelet and 
RBC engraftment. Maturing trilineage 
hematopoiesis and no evidence of 
fibrosis, but platelets remain 
decreased, ~119-142 x109/L.  
1-III-9 2 y F 8.39 11.9 468 72.0 8.2 microcytosis CAH, mild 
iron 
deficiency 
ND ND ND none 11:01 
11:01 
41:01 
41:01 
07:01 
07:01 
08:04 
08:04 
03:01 
03:01 
c.61_61+1dup/ 
c.61_61+1dup 
Clinically unaffected, rare giant 
platelets 
2-II-5 7 y M 5.43 11.7 
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80.5 NA anisopoikilocytosis, 
microcytosis, 
ovalocytes, burr cells, 
helmet cells, 
acanthocytes, 
schistocytes, frequent 
large platelets 
None ND ND ND none 23:01 
23:01 
50:01 
50:01 
06:02 
06:02 
04:06 
04:06 
04:02 
04:02 
c.147insT 
p.Ala52GlyfsX128 
Observation, stable disease 
2-II-6 6 m M NA 5.4 10 65.0 12-24 anisopoikilocytosis, 
microcytosis, 
elliptocytes, 
schistocytes, frequent 
large platelets 
None Neg Neg Neg IVIG x1 
Steroids x1 
with  
transient 
responses 
23:01 
23:01 
50:01 
50:01 
06:02 
06:02 
04:06 
04:06 
04:02 
04:02 
c.147insT 
p.Ala52GlyfsX128 
Observation, stable disease  
3-II-4 17 
m 
F 19.2 5.1 81 71.3 NA 
 
anisopoikilocytosis, 
microcytosis, target 
cells, ovalocytes, burr 
cells, tear drop cells, 
schistocytes, frequent 
large platelets 
CAH, 
asplenia 
Neg Neg Neg none 11:01 
11:01 
41:01 
41:01 
07:01 
07:01 
08:04 
08:04 
03:01 
03:01 
c.61_61+1dup/ 
c.61_61+1dup 
Observation, stable disease 
4-II-2 18 
m 
M NA 5.4 96 NA NA Anisopoikylocytosis, 
target cells, 
schistocytes, 
leptocytes, dacryocytes, 
Howell-Jolly bodies 
cerebral 
cavernoma 
ND Neg ND IVIG and 
steroid, no 
response 
ND ND ND ND ND c.469G>A 
p.Gly157Arg 
Observation, stable thrombocytopenia, 
supportive care with platelets 
4-II-3 1 y F 17 12.5 97 NA NA Anisopoikylocytosis, 
target cells, 
schistocytes, 
leptocytes, dacryocytes, 
Howell-Jolly bodies 
None ND ND ND none ND ND ND ND ND c.469G>A 
p.Gly157Arg 
Observation, stable mild/moderate 
thrombocytopenia 
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Table 2.  Peripheral blood counts of indicated mouse genotypes 
 
Hematological 
parameters 
WT 
n=36 
G6b+/hu 
n=37 
G6bhu/hu 
n=37 
G6bhu/- 
n=31 
G6b-/- 
n=37 
λ P 
Platelets 
(109/L) 
1118 ± 209 1127 ± 219 884 ± 214*** 795 ± 187*** 206 ± 86*** 
0.2 2 × 10-72 
Mean platelet 
volume (fl) 
5.8 ± 0.2 5.8 ± 0.2 6.1 ± 0.5*** 6.2 ± 0.4*** 7.8 ± 0.4*** 
-2 2 × 10-65 
Plateletcrit 
(%) 
0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.1 ± 0 
- - 
Red blood 
cells (1012/L) 
11.1 ± 0.7 10.5 ± 0.7 10.7 ± 0.8 10.4 ± 0.6 10.0 ± 0.6 
- - 
Hematocrit 
(%) 
33.6 ± 2.4 32.7 ± 1.8 33.1 ± 2.5 34.1 ± 1.9 31.8 ± 1.7 
- - 
White blood 
cells (109/L) 
7.5 ± 3.6 8.6 ± 2.3 7.4 ± 2.6 10.1 ± 6.1 13.1 ± 6.8*** 
0.5 8 × 10-7 
Lymphocytes 
(109/L) 
6.2 ± 2.7 7.4 ± 2.0 6.9 ± 2.2 7.8 ± 3.7 11.8 ± 4.9*** 
0.5 3× 10-11 
Monocytes 
(109/L) 
0.5 ± 0.4 0.3 ± 0.2 0.5 ± 0.2 0.3 ± 0.3 0.5 ± 0.4 
- - 
Neutrophils 
(109/L) 
0.8 ± 0.4 0.9 ± 0.4 0.7 ± 0.3 1.2 ± 0.8 1.7 ± 1.1 
- - 
Eosinophils 
(109/L) 
0.1 ± 0.2 0 ± 0 0 ± 0 0 ± 0.1 0 ± 0  
- - 
Basophils 
(109/L) 
0.1 ± 0.3 0 ± 0 0.1 ± 0.2 0 ± 0.1 0.1 ± 0.1  
- - 
 
 
All values expressed as mean ± SD. 
λ is the coefficient for the power transformation to minimize heteroscedasticity and non-normality 
P is the result of a one-way ANOVA on transformed data 
*** indicates P < 0.001 compared to WT with Dunnett’s post hoc test  
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Figure legends 
 
Figure 1.  cMTFM is due to mutations in G6b-B (G6b).  (A) Family pedigrees. Black arrows 
point to the probands in each family.  Double line indicates a consanguineous relationship.  
Ages are provided at the time of the initial evaluation of the youngest affected individual in the 
family.  For the deceased proband the age at diagnosis and age of death is listed.  (B) 
Ideograms showing cMTFM linkage region, the G6b (MPIG6B) locus and patient mutations.  
(C) Expression of p.Gly157Arg mutant in DT40 cells leads to (C) protein instability and (D, E) 
reduced expression on the surface of the cell (mean ± SEM, n=2).  pcDNA3 vector, grey; G6b-
B WT, green; G6b-B p.Gly157Arg, red, MFI, median fluorescence intensity, representative 
blots and histograms of two independent experiments. 
Figure 2.  Pathology of cMTFM.  Wright-Giemsa stained peripheral blood smears from (A) a 
normal control, (B) patient 3-II-4 and (C) the clinically unaffected, genotypically G6b-mutated 
individual 1-III-9. Note the large, hypogranular platelets (arrow) and RBC anisocytosis in 3-II-4 
and the rare giant platelet in 1-III-9 (arrow).  Serial histologic sections of a bone marrow 
biopsies from (D, G, J, M) a normal control individual, (E, H, K, N) 3-II-4, and (F, I, L, O) 1-III-9 
stained with (D-F) H&E, (G-I) Reticulin, (J-L) the megakaryocytic marker CD61, and (M-O) 
G6b-B.  Atypical megakaryocytes present in stellate clusters associated with increased 
reticulin staining are characteristic of cMTMF.  Staining for G6b-B is entirely negative in the 
megakaryocytes and platelets from 3-II-4 and 1-III-9. 
Figure 3.  Expression of G6b isoforms in humanized mouse model.  (A) WT, G6bhu/+, 
G6bhu/hu, human and G6b-/- washed platelet lysates (4 × 108/mL), were resolved by SDS-PAGE 
and custom antibodies used to detect mouse (m)G6b-B, human (h)G6b-B and hG6b-A.  
Expression was quantified and normalized to (i) WT or (ii, iii) human lysates, to show relevant 
 
 
 
 
 
 
30 
expression levels in the mouse models.  (B) Quantification of glycosylated and unglycosylated 
human G6b-A and -B, data normalized to show percentage of total expression.  (C) hG6b-B 
was immunoprecipitated (IP) from basal and collagen activated G6bhu/hu and human washed 
platelet lysates (4 × 108/mL).  Co-IP of Shp1 and Shp2 was investigated by (i) SDS-PAGE 
before (ii) quantification and normalization to hG6b-B levels.  Quantification was completed 
using Licor Odyssey system. All data represented as mean ± SEM (n=3-4), *** P<0.001. 
Figure 4.  Minor alterations of G6bhu/hu platelet functional responses.  (A) Averaged 
aggregation and ATP release traces for washed platelets (2 × 108/mL) activated with indicated 
concentrations of CRP and anti-CLEC-2 antibody (Ab).  Area under the curve (AUC) 
quantification of (iii) platelet aggregation and (iv) ATP release (n=5-6 per condition, ** P<0.005 
and * P<0.05).  (B) Heparin-PPACK-fragmin anti-coagulated whole blood was flowed over 
glass coverslips coated with collagen immediately following collection.  (i) Brightfield images 
were immediately collected, followed by staining with PE-conjugated JON/A, FITC-conjugated 
P-selectin and Alexa647-conjugated Annexin V and fluorescence imaging.  Analysis 
quantifying (ii-vi) thrombus surface area coverage and morphological scores of adhered 
platelets, (n=5-6, *** P<0.001, ** P<0.005) and (vii-ix) surface area coverage of fluorescently 
labeled antibodies (n=5-6, *** P<0.001, * P<0.05).  (C) Total blood loss to body weight ratio of 
mice following excision of tail tip (n=12-16, *** P<0.001, ** P<0.005).  All data collection and 
analysis in panels B and C were completed blinded, mean ± SEM, scale bar: 10 m 
Figure 5.  Altered tyrosine phosphorylation in response to GPVI and CLEC-2 agonists in 
G6bhu/hu platelets.  Representative blots (n=3) of lysates prepared from washed platelets (4 × 
108/mL) activated with indicated concentrations of (A) CRP (90 s, 10 M lotrafiban, 10 M 
indomethacin and 2 U/ml apyrase) or (B) CLEC-2 Ab (300 s, 10 M lotrafiban) and probed with 
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the indicated antibodies.  Src family kinase (SFK) phosphotyrosine (pTyr)418 and Syk 
pTyr519/20 were quantified using ImageJ and normalized to total tubulin and Syk reblots, 
respectively. 
Figure 6.  Further reduction in hG6b-B expression exacerbates observed phenotype.  (A) 
G6bhu/hu mice were crossed with G6b-/- mice to produce hemizygous (G6bhu/-) mice.  (ii) 
Representative blots and (iii) quantification of hG6b-B expression in the indicated genotypes 
(n=3).  (B) Average aggregation and ATP release traces and quantification of area under the 
curve (AUC) investigating functional response of G6bhu/- mouse washed platelets (2 × 108/mL) 
in response to indicated agonists (n=5-6, *** P<0.001, * P<0.05).  All bar graphs presented as 
mean ± SEM. 
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Supplementary materials 
Methods 
Antibodies and reagents 
FITC-conjugated P-selectin, GPVI, GPIb and 2 and R-phycoerythrin (PE)-conjugated 
JON/A antibodies were from Emfret Analytics (Eibelstadt, Germany); PE-conjugated anti-
IIb antibody from BD Biosciences (Oxford, UK); phalloidin-488 from Thermo Fisher 
(Loughborough, UK); rat anti-mouse CLEC-2 antibody from Serotec (Oxford, UK) and 
Alexa488-conjugated goat anti-rat antibody from Life Technologies (Paisley, UK). G6b-B 
specific antibodies were raised as previously described.33 For immunoblotting, anti-Shp1 
and anti-Shp2 antibodies were from Santa Cruz Biotechnology (Dallas, TX, USA); anti-
phosphotyrosine (p-Tyr) from Merck Millipore (Nottingham, UK); Src phosphotyrosine-418 
(Src p-Tyr418) from Life Technologies (Loughborough, UK) and Syk phosphotyrosine-
525/26 (Syk p-Tyr525/526) from Cell Signaling Technology (Hitchin, UK). All other reagents 
were from Sigma-Aldrich (Poole, UK), unless stated otherwise.  Custom monoclonal mouse 
anti-human G6b extracellular domain, monoclonal rabbit anti-mouse G6b extracellular 
domain and polyclonal rabbit anti-human and –mouse G6b-B antibodies were generated by 
Biogenes (Berlin, Germany) as previously described (Mazharian et al, Sci Sign, 2012).  
Custom rabbit polyclonal antibodies for human G6b-A were raised against the intracellular 
tail of G6b-A (Biogenes, Berlin, Germany). 
Genotype confirmation using Sanger sequencing 
The G6b locus (NM_138272.2) was amplified with a single primer pair long range (LR) F & 
LR R1 with Bio-RadBioRad iProof HF master mix (Bio-Rad Laboratories, Hercules, CA), 
and sequenced with the same LR primers as well as primers designed to flank each exon. 
A description of the primers and Sanger sequencing conditions is shown in Supplementary 
Table 2. 
DNA constructs 
The cDNA encoding the human G6b-B protein was amplified by PCR from a human cDNA 
library. This PCR fragment was first cloned into the pCR®-Blunt vector (Invitrogen, Paisley, 
UK), and then subcloned into the pcDNA3 vector, for expression of untagged G6b-B in 
heterologous cell systems. The construct expressing the p.Gly157Arg mutant was 
generated by site directed mutagenesis (Genscript, Piscataway, NJ, USA). 
Cell culture  
DT40 chicken B cells were grown in RPMI supplemented with 10% fetal bovine serum, 1% 
chicken serum, 100 units (U)/ml penicillin, 100 g/ml streptomycin, 50 M -
mercaptoethanol, and 20 mM glutamine.  2 g of G6b-B WT, G6b-B Gly157Arg or empty 
pcDNA3 vector were transfected by electroporation at 350 V and 500 microfarads into 2 x 
107 cells DT40 cells, (resuspended in 400 l serum free medium).  Twenty hours after 
transfection, live cells were counted by trypan blue exclusion, and G6b-B expression levels 
were analyzed via flow cytometry and western blotting.  Flow cytometry data presented as 
media fluorescence intensity. 
G6b humanized mouse 
To create the humanized G6b mouse, a targeting vector containing the human G6b 
genomic locus, a puromycin resistance cassette flanked by Flp-recombinase targeting sites 
and two homology arms was produced and inserted into the genome of C57BL/6NTac 
mouse embryonic stem cells by homologous recombination. Validated clones were injected 
into mouse blastocysts, before implanting into pseudo-pregnant female mice. Removal of 
the puromycin resistance cassette by a Flp recombinase expressing mouse subsequently 
allowed for WT and KI mice to be distinguished by PCR targeting the residual Flp-
recombinase recognition site (Figure S1D, E). This KI strategy effectively knocked-out 
mouse G6b and allowed for physiologically normal promotor driven expression of human 
G6b in its place. 
Mouse hematology 
ACD anticoagulated whole blood was collected and blood cells counted using an ABX 
Pentra 60 hematological counter (Horiba Medical, Northampton, UK).  Platelet count, 
platelet volume, white blood cell count and lymphocyte count data were normalized using a 
modified Box-Cox power transformation: 
𝑦′ =
(𝑦𝜆 − 1)
𝜆
+  𝜆 
When λ = 1: y' = y (No transformation) 
When λ = 0: y' = ln(y) (natural log transformation) 
Transformed data were verified to be normally distributed using Browne-Forsythe test for 
equal variance before being analyzed by one-way ANOVA with Dunnett’s post-hoc test to 
compared each genotype to WT. 
Flow cytometry 
ACD anticoagulated whole blood were incubated with indicated FITC- and PE-conjugated 
antibodies before measuring using an Accuri C6 flow cytometer (BD Biosciences, Oxford, 
UK). 
Platelet functional assays 
Washed platelets (2 × 107/mL) were allowed to adhere and spread on fibrinogen-coated 
coverslips as previously described.47 All slides were imaged using a Zeiss Axiovert 200M 
microscope and blinded images quantified using ImageJ.  Stages of platelet spreading were 
categorized as unspread, formation of filopodia, formation of lamellipodia and fully spread 
(Figure S15).  Platelet aggregation and ATP release was measured as previously described 
using washed platelets (2 × 108/mL) and a Chronolog Model 700 aggregometer.48 ADP 
sensitive platelets were prepared as previously described.49  For flow adhesion glass 
coverslips were coated as previously described,50 and anti-coagulated whole blood (final 
concentrations: 40 M PPACK, 5 U/ml heparin and 50 U/ml fragmin) flowed over for 3.5 
minutes immediately following collection of blood.  Images were captured with an EVOS 
microscope (Life Technologies, Carlbad, CA, USA) and blinded images analyzed using Fiji 
(Figure S11). 
 
Supplemental Data: Clinical Case Descriptions 
Family 1 
Patient 1-III-1 
Patient 1-III-1 was the male child of consanguineous parents (first cousins) of Arabic decent 
from the United Arab Emirates (UAE).  The boy was born full term via normal spontaneous 
vaginal delivery (NSVD) following an uneventful pregnancy.  The neonatal period was 
complicated by prolonged jaundice and dehydration.  He was subsequently diagnosed with 
salt wasting due to congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency 
as a consequence of a homozygous intron 2 mutation (c.293-13C>G) in the CYP21A2 
gene).  He was started on hydrocortisone and fludrocortisone supplementation with good 
clinical improvement.  He was doing well until 5 months of age when he presented with 
prolonged epistaxis.  A complete blood count (CBC) revealed anemia with a hemoglobin 
(HGB) of 5.0 g/dL and thrombocytopenia with 20x109/L.  The white blood cell count (WBC) 
was not available.  The infant received packed red blood cells (PRBC) and platelet 
transfusions.  His platelet count transiently improved to ~100x109/L.  He remained 
thrombocytopenic with platelet counts ranging between 6-24 x109/L and required 
intermittent platelet transfusions (6 total).  He also had a microcytic anemia with HGB 
ranging between 5-8 g/dL requiring occasional PRBC transfusions (3 total).  The patient’s 
bleeding symptoms were mild with occasional episodes of mild epistaxis and an episode of 
oozing from the bone marrow (BM) biopsy site requiring PRBC and platelet transfusion. 
A BM aspirate and biopsy performed at another institution at 8½ months of age was 
interpreted as refractory cytopenia with myeloid dysplasia with no excess in blasts.  
Cytogenetics were reported to be normal.  Concurrent blood counts showed a WBC count 
of 12.8x109/L, HGB 9.3 g/dL with a mean corpuscular volume (MCV) of 72 fl and platelets of 
16x109/L.  Hematopoietic stem cell transplantation (HSCT) was considered at the time but 
sibling donor evaluation was logistically difficult and HSCT was deferred.  
Additional workup revealed a normal fetal HGB, negative viral studies (cytomegalovirus 
(CMV), Epstein-Barr virus (EBV)), no evidence of paroxysmal nocturnal hemoglobinuria 
(PNH) by flow cytometry and normal diepoxybutane (DEB) induced chromosomal breakage 
making an underlying Fanconi Anemia unlikely.  His IgG was 592, IgA 63, and IgM 102.  His 
lactate dehydrogenase (LDH) was elevated at 1091 (normal reference range 500-920).  His 
peripheral blood (PB) smear showed mild leukocytosis, microcytic anemia with 
anisopoikilocytosis showing target cells, ovalocytes and thrombocytopenia with enlarged 
platelets.  A repeat BM aspirate and biopsy at 13 months showed a hypercellular marrow 
for age with minimal granulocytic and erythroid dysplasia with a decreased myeloid-to-
erythroid ratio (1:1) and moderate megakaryocytic dysplasia.  Blasts were not increased.  
The biopsy revealed marked reticulin fibrosis.  An iron stain was negative for ringed 
sideroblasts.  Concurrent cytogenetic studies showed a normal male karyotype of 46, XY 
and negative fluorescence in situ hybridization (FISH) for del5q and monosomy 7.  Overall 
the findings were thought to be consistent with a myeloproliferative or myelodysplastic 
process, although JAK2 mutation analysis was negative. 
Based on his persistent thrombocytopenia and anemia with ongoing transfusion needs he 
was referred for HSCT.  A suitable matched sibling, unrelated donor or alternative donor 
was not available.  Therefore, a haploidentical peripheral blood stem cell transplant 
(PBSCT) from the mother was done, using a submyeloablative conditioning regimen with 
Campath 1H, Fludarabine 30mg/m2x4 doses and total body irradiation (TBI) 600cGy 
(HIMSUM, clinicaltrials.gov NCT00058825).  Documentation of the cell dose and graft 
manipulation procedures were not available.  Unfortunately, the patient failed to engraft with 
less than 10% BM cellularity comprised of all male karyotype cells on day 20 after his 
HSCT.  He subsequently developed gram-negative bacterial sepsis and underwent a 
second haploidentical PBSCT from his mother ~50 days after his first PBSCT.  
Unfortunately, he developed progressive multiorgan failure, sever upper gastrointestinal 
bleeding due to a duodenal ulcer requiring several surgical interventions, renal and 
respiratory failure, and acute respiratory distress syndrome (ARDS), and succumbed from 
transplant related complications. 
Patient 1-III-5 
Patient 1-III-5, the 5-year old younger brother of 1-III-1, was born at full term via NSVD.  He 
was cared for in the UAE during the first 10 months of his life.  He was diagnosed with 
congenital adrenal hyperplasia (CAH) in the first week of life and received supplementation 
with hydrocortisone and fludrocortisone.  He presented with bruising and petechiae on his 
upper chest on the first day of life.  Given the family history of thrombocytopenia, a 
complete blood count (CBC) was obtained and showed a platelet count of 23x109/L.  He 
received a platelet transfusion with a post-transfusion count of 141x109/L but quickly 
dropped again to 71 x109/L.  His HGB and WBC were normal for age.  A direct Coombs test 
was negative.  A BM aspirate and biopsy at birth resulted in a non-diagnostic specimen.  
His initial workup included serology studies for TORCH infections (Toxoplasmosis, Other 
(syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes 
infections), which were negative.  Mutation analysis for Wiskott-Aldrich syndrome was 
negative. 
Given recurrent thrombocytopenia at 10 days of life he was treated with IVIG 1mg/kg IV x 2 
days which improved his platelet count from 13x109/L to 61x109/L.  Serial CBCs over the 
next several months documented platelet counts between 50 x109/L and 90x109/L.  By 6½ 
months of age he had recurrent severe thrombocytopenia to 16x109/L and a new anemia 
with a HGB of 6.9 g/dL and received blood and platelet transfusions.  A repeat BM showed 
a hypocellular, hemodilute aspirate with frequent lymphocytes.  The biopsy revealed 
increased megakaryocytes and associated reticulin fibrosis similar to that seen in his older 
brother 1-III-1. 
Beginning at 7-months of age, the patient became transfusion dependent for platelets, 
which he received every 10-days. He also required intermittent PRBC transfusions for a 
microcytic anemia.  He never had leukopenia or neutropenia; his WBC was mildly elevated.  
He received a total of 3 IVIG treatment courses at day of life 10, and two- and four-months 
of age.  He only showed a partial and transient improvement in his platelet count.  His 
bleeding symptoms were mild to moderate with epistaxis, petechiae, frequent bruising and 
ecchymosis.  He had one prolonged episode of epistaxis lasting for 12-hours, requiring 
transfusion support.  The patient had normal growth and development and did not have 
hepatosplenomegaly on exam. 
He transitioned care to our medical center at 10-months of age.  A repeat BM aspirate and 
biopsy showed a cellular marrow with increased atypical megakaryocytes, occurring in 
clusters and associated marrow fibrosis.  These findings confirmed the diagnoses of cMF 
and were consistent with those observed in his older brother. His genetic work up included 
negative mutation analysis for MPL, JAK2 and VPS45. 
The patient had the same identical human leukocyte antigen (HLA) type as his older brother 
(1-III-1).  A repeat unrelated donor (URD) search did not reveal any acceptable HLA 
matched donors for HSCT consideration.  In the meantime, the patient’s aunt and uncle 
(also 1st cousins) had two additional children (1-III-8 and 1-III-9).  1-III-9 was found to be a 
10/10 identical HLA match, but was also affected by CAH.  She was considered as a 
related donor and underwent a work up to rule out cMF.  Her CBC showed a mildly elevated 
WBC but no thrombocytopenia or anemia.  Her marrow showed lymphoid aggregates with 
mild fibrosis around the lymphoid aggregates.  Her megakaryocytes were normal.  Given 
the ongoing concern for an underlying inherited disorder we opted not to offer an upfront 
matched related donor (MRD) HSCT. 
The patient remained transfusion dependent and treatment with a high dose steroid pulse 
(methylprednisone 30mg/kg x 3 days) followed by a slow taper was initiated.  After 7-weeks 
he showed a partial response with platelet counts as high as 47x109/L.  A second steroid 
pulse with 1mg/kg methylprednisone was administered, to which his maximum platelet 
response was 89x109/L.  Unfortunately, the response was not sustained and his platelets 
decreased with the steroid taper, and ultimately reverted to 10x109/L after he contracted 
primary varicella zoster infection. 
Given that he remained transfusion-dependent, we re-considered the cousin (1-III-9) as the 
only MRD available.  She underwent serial blood count and BM evaluations.  Her blood 
counts remained normal and her BM on future studies was reassuring with normal 
megakaryocytes and minimal fibrosis in association with lymphocytes (see description 
below).  None of those findings resembled those seen in the cousins and not diagnostic of 
cMF.  The patient ultimately underwent a MRD HSCT from his cousin at 2-years of age.  
The patient was conditioned with a fully myeloablative conditioning regimen with busulfan 
and cyclophosphamide and received cyclosporine (CSA) and a short course of 
methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis.  Bone marrow was 
used as stem cell source with a cell dose of 4.32x108 total cells/kg.  His transplant course 
was uncomplicated without major infections, organ toxicity or GVHD.  He engrafted myeloid 
cells on day +34 and became RBC transfusion independent on day +39.  He had delayed 
platelet engraftment, becoming transfusion independent on day +60 and reached over 
100x109/L on day + 178.  Blood counts at 21-months post-transplant were entirely normal 
with a WBC of 10.61 x109/L, HGB 13.7 g/dL, and platelets 343 x109/L.  His MCV was 
normal at 80.5 fl (previously microcytic). 
His BM aspirate and biopsy 4 and 8 months after HSCT showed a mildly hypocellular 
marrow with maturing trilineage hematopoiesis and a mildly increased myeloid-to-erythroid 
ratio.  Megakaryocytes were present in normal numbers and morphology.  Reticulin was 
minimally increased but markedly decreased from his pre-HSCT BM studies.  All concurrent 
cytogenetic studies showed a normal female karyotype and negative FISH for monosomies 
5 and 7, trisomy 8 and partial deletions of long arms of chromosomes 5, 7 and 20.  Whole 
blood chimerism showed slight decrease in donor chimerism (93% donor, 7% recipient) but 
his blood counts remained normal. 
Patient 1-III-6 
During our evaluation of 1-III-5, the mother of 1-III-1 was pregnant with another male fetus.  
Amniocentesis confirmed that the fetus also had an intron 2G mutation in the CYP21A2 
gene and would be affected by CAH.  HLA typing on the amniotic material showed the 
same homozygous HLA type found in his two older brothers (1-III-1 and 1-III-5).  The baby 
was born full term and managed for his CAH.  Given the family history of cMF, blood counts 
were followed closely.  His platelet count at birth was 50x109/L, but recovered to 132x109/L 
and 270x109/L at 2 and 4 weeks of life, respectively.  A repeat evaluation at 5 months of 
age, however, showed leukocytosis, microcytic anemia and thrombocytopenia with a WBC 
of 13.79x109/L, HGB 8.7 g/dL and platelets of 19 x109/L, raising concern that the infant was 
affected by cMF as well.  A BM showed findings identical to his two affected brothers, 
including increased reticulin fibrosis and atypical megakaryocytes.  Concurrent cytogenetics 
studies were normal.  The patient, who was HLA identical to his brothers (1-III-1 and 1-III-5) 
and cousin (1-III-9) was carefully monitored while his older brother underwent a MRD HSCT 
from their cousin, 1-III-9.  Between age 5 and 16 months of age his platelet count ranged 
from 15 to 25 x109/L.  His WBC and HGB ranged from 6.2 to 17.17x109/L and 7.8 to 
9.7g/dL respectively.  During this period of observation, he received three platelet 
transfusions and showed mild bleeding symptoms, including several hematomas and 
episodes of epistaxis.  He returned to the UAE, where, at 17-months of age, he had 
significant gum bleeding and epistaxis and received platelet transfusions, but did not show 
an improvement in his platelet count.  He received a dose of IVIG, which transiently 
improved his platelets to 100x109/L.  A repeat BM at 14-months of age showed 
normocellular marrow for age (95% cellularity), increased atypical megakaryocytes often 
occurring in clusters, and worsening reticulin fibrosis (grade 3).  His genetic work up 
included negative mutation analysis for MPL, JAK2 and VPS45.  
Given the successful HSCT of his older sibling from their fully matched related donor, and 
the lack of another related, unrelated or alternative donor source, we opted to perform the 
same HSCT for this patient.  Prior to proceeding we confirmed that the donor remained 
unaffected with normal blood counts and a normal BM aspirate and biopsy.  1-III-6 
underwent a fully MRD HSCT with myeloablative conditioning regimen comprised of 
busulfan and cyclophosphamide.  GVHD prophylaxis consisted of cyclosporine A (CSA) 
and a short course of methotrexate (MTX).  His transplant course was largely 
uncomplicated.  He had delayed myeloid engraftment at day +45 and delayed platelet and 
red cell engraftment requiring intermittent platelet transfusion.  A BM study on day +95 
showed a mildly hypocellular marrow for age with normal myeloid-to-erythroid ratio and 
normal maturation.  Megakaryocytes were mildly decreased but morphologically normal. 
Reticulin stain did not show evidence of reticulin fibrosis.  Serial BM chimerism studies 
showed over 97% donor chimerism in all lineages (T-cells, B-cells and myeloid fraction).  
His laboratory studies showed evidence of hemolysis and it was felt his anemia and 
thrombocytopenia might be due to mild transplant-associated thrombotic microangiopathy 
(TA-TAM) due to CSA, and he was switched with Tacrolimus for GVHD prophylaxis.  He 
received several doses of darbopoietin due to low erythropoietin levels.  
His anemia and thrombocytopenia slowly improved beginning day +120 after his HSCT. His 
HGB level eventually normalized on day +136.  Other than mild chronic oral GVHD at day 
+150, for which he was treated with topical steroids and topical tacrolimus, he experienced 
no significant organ toxicities or infections. 
Due to persistent thrombocytopenia a repeat marrow was performed 1 year post-HSCT and 
showed a mildly hypocellular marrow for age with maturing trilineage hematopoiesis and no 
evidence of reticulin fibrosis.  Megakaryocytes were mildly decreased, occasional occurred 
in small clusters but morphologically normal appearing.  His BM chimerism studies 
remained 100% donor. 
Patient 1-III-9 
1-III-9 is the cousin of proband 1-III-1 and his brothers 1-III-5 and 1-III-6. She is the product 
of a consanguineous relationship (first cousins) of Arabic decent from the United Arab 
Emirates.  The parents of 1-III-1 and 1-III-9 are siblings to each other (Figure 1A). 
Individual 1-III-9 was also diagnosed with CAH shortly after birth.  She underwent surgical 
correction with vaginoplasty.  HLA typing in search for a potential related donor for 1-III-5 
showed an identical homozygous HLA type to the proband 1-III-1, 1-III-5 and 1-III-6.  She 
was considered as a potential marrow donor for 1-III-5. Given the concern for an underlying 
inherited cause of the families’ cMF she underwent careful diagnostic evaluation, which 
included serial CBCs that were all normal.  A BM study at 14-months of age showed a 
normocellular marrow for age with numerous lymphoid aggregates that contained germinal 
centers.  The myeloid-to-erythroid ratio was increased.  Myeloid and erythroid elements 
showed normal maturation and no dysplasia.  Megakaryocytes were normal in number and 
morphology.  Reticulin stain showed a slight increase in reticulin in association with the 
lymphoid aggregates.  Concurrent cytogenetic and FISH studies for monosomies 5 and 7 
and trisomy 8 were negative.  Lymphoid aggregates at this age can be seen in 
autoimmunity, but a detailed family history and screening laboratory studies for an 
autoimmune disorder were negative.  Given the unknown significance of the lymphoid 
aggregates in the marrow, her donor status for her male cousin (1-III-5) was placed on hold.  
A repeat BM at 16 months showed resolution of the lymphoid aggregates and no evidence 
of a cMF. 
Her cousin 1-III-5 was treated with high dose steroids (see above) but did not show a 
sustained response and remained transfusion dependent.  We therefore performed a 
reevaluation of 1-III-9.  Blood counts remained entirely normal with WBC 8.39x109/L, HGB 
11.9 g/dL, platelet count 468x109/L.  A repeat BM at 2 years and 6 months showed a 
normocellular marrow for age with maturing trilineage hematopoiesis with relative erythroid 
and mild megakaryocytic hyperplasia.  
Given the lack of features diagnostic of cMF and the ongoing transfusion needs of her 
cousin 1-III-5, we discussed treatment options with both families.  After carefully 
consideration, informed consent regarding the theoretical risk for an underlying genetic 
diagnosis for which 1-III-9 could be a non- or minimally- expressing carrier, 1-III-9 was used 
as a marrow donor for 1-III-5.  The transplant was successful with prompt myeloid 
engraftment and delayed platelet engraftment likely due to remodeling of hematopoietic 
niche due to reticulin fibrosis.  Ultimately 1-III-5 achieved robust trilineage engraftment with 
normal blood counts and a normal marrow. 
A follow up marrow was performed at 4-years of age to assess if she could serve as a 
donor for the other cousin, 1-III-6, who was also platelet transfusion dependent.  The BM 
showed a mildly hypocellular marrow for age with maturing trilineage hematopoiesis and 
normal myeloid and erythroid maturation.  Megakaryocytes were present in normal numbers 
and morphologically unremarkable.  Reticulin fibrosis was not present.  No lymphoid 
aggregates were noted.  The blood counts remained normal. 
Family 2 
Patient 2-II-6 
The proband (2-IV-6) is a child of a consanguineous family of Arabic decent; the parents 
are first cousins from Saudi Arabia (Figure 1).  The patient was a male born at 36 weeks via 
caesarian section due to premature rupture of membranes and fetal distress.  He required a 
brief period of non-invasive ventilation with a neonatal intensive care unit (NICU) stay of 1-
month.  During his first month of life, serial CBCs were performed, which showed mild 
thrombocytopenia with a platelet count of 112x109/L with a normal HGB and WBC count.  
His platelet count improved to 161x109/L by the time of discharge.  He had a follow up CBC 
at 3 months of age, which showed a normal platelet count of 220x109/L, HGB 10g/dL, and 
MCV of 97fl.  WBC was reported as “normal”.  The patient was doing well until 6-months of 
age when a routine CBC showed severe thrombocytopenia (platelet count 10x109/L) and 
microcytic anemia (HGB 5.4g/dL, MCV 65fl).  He received RBC and platelets transfusion 
and was treated for a presumed immune mediated cytopenia and with IVIG and steroids.  
He showed some improvement in his blood counts with a maximum platelet count of 
127x109/L.  Unfortunately, the improvement in his platelet count was never sustained and 
his platelet count dropped as soon as steroids were tapered.  He received a total of 4 
courses of steroids and several doses of IVIG.  The patient required 6-8 RBC and 
approximately 10 platelet transfusions.  His microcytic anemia was treated with iron 
supplementation, but did not lead to improvement in his anemia. 
From a clinical perspective, he showed objective signs of bleeding including mucosal 
bleeding (lower gastrointestinal and oral mucosa), easy bruising and oozing from a bone 
marrow procedure site, requiring a transfusion.  He had mild decrease in energy due to 
anemia.  Three BM studies were performed at 12-, 14- and 24-months and overall showed 
a normocellular marrow with trilineage hematopoiesis and normal numbers of 
megakaryocytes.  Reticulin stain at 24-months was negative. 
A follow up marrow at 3 years of age showed a hypercellular marrow for age with maturing 
trilineage hematopoiesis and increased lymphocytes, including young forms and 
hematogones and moderate myelofibrosis (reticulin fibrosis grade 1-2+). 
His work-up included normal blood chemistries, liver function tests, iron studies, ferritin 45, 
iron saturation 45% and elevated hepcidin of 437.5 ng/ml.  Vitamin B12, Vitamin D, and 
folate were normal.  Platelet autoantibodies were detected against GP IIb/IIIa and Ib/IX.  An 
autoimmune work up (ANA, auto-antibody screen) and autoimmune lymphoproliferative 
syndrome (ALPS) panel was negative.  Lymphocyte subsets and immunoglobulins were 
normal, except IgM was decreased at 30 mg/dL.  A gene sequencing panel for inherited BM 
failure syndromes, globin disorders and myeloproliferative neoplasms (JAK2, MPL, CALR) 
and VPS45 was negative.  Platelet function and aggregation studies could not be 
performed due to low platelet count. 
Due to concern for a congenital disorder and the potential need for HSCT, HLA typing was 
performed revealing a homozygous HLA type, although different from that present in 
Families 1 and 3. 
Patient 2-II-5 
Patient 2-IV-5 is the older brother of 2-IV-6 who was noted to have macrothrombocytopenia 
on a CBC following his brother’s diagnosis.  He has a stable platelet count, ranging from 45 
to 107x109/L.  His blood counts and smear showed mild leukopenia, no neutropenia, aniso-
and poikilocytosis with a HGB of 8.8g/dL. 
All of the siblings of the other siblings are reported to have iron deficiency anemia with a 
HGB of <10 g/dL.  All of the father’s sisters are reported to have iron deficiency anemia and 
are reported to be on iron supplementation.  Platelet counts in those relatives are thought to 
be normal.  The family history was also significant for diabetes and hypertension in the 
grandparents, liver cancer in the father’s aunt and gastric cancer in the grandmother.  There 
is no history of bleeding disorders or thrombocytopenia. 
Family 3 
Patient 3-II-4 
The proband (3-IV-4) was referred to our medical center at 18-months of age for work up of 
cMF. She was born at full-term and is the 4th living child of a consanguineous family 
(parents are first cousins) from the UAE (Figure 1).  At birth, the patient had ambiguous 
genitalia and was diagnosed with CAH due to 21-hydroxylase deficiency.  She has been 
managed with hydrocortisone and fludrocortisone.  She was doing well until 15 months of 
age when she was found to be pale.  Her blood counts showed leukocytosis (WBC 19.2 
cells x109/L), microcytic anemia (HGB 5.1g/dL, MCV 71.3, reticulocytes 1.5%) and 
thrombocytopenia 81 x109/L.  She did not have any hepatosplenomegaly, lymphadenopathy 
or dysmorphic features.  The peripheral blood smear demonstrated anemia with marked 
anisopoikilocytosis (target cells, schistiocytes) and occasional nucleated red blood cells.  
Leukocytosis with left myeloid cells and immature forms and thrombocytopenia with variable 
sized platelets including larger forms was noted. Platelet granulation was normal.  
A BM aspirate and biopsy showed a mildly hypercellular marrow for age (90% cellularity) 
with a relative myeloid hyperplasia.  Myeloid and erythroid elements matured normally.  
Megakaryocytes were increased, showed variable morphologic abnormalities including 
small hypolobated forms, and occurred in clusters.  Blasts were not increased.  Scattered 
small lymphocytes appeared normal.  Mildly increased eosinophils were noted.  A reticulin 
stain showed mild to moderately increased fibrosis (grade 1-2 out of 3).  
Immunohistochemistry (IHC) for CD61 showed increased megakaryocytes, focally 
clustering.  The BM aspirate was hypocellular and aspicular and likely not representative, 
due to marrow fibrosis.  
Her work-up included a normal chest x-ray with no bony abnormalities.  She underwent an 
abdominal ultrasound to evaluate possible hepatosplenomegaly and was found to have 
asplenia.  Laboratory testing was negative for nutritional deficiencies (iron, B12, folate).  
1,25-dihydroxy Vitamin D was mildly elevated at 89.2.  Chemistry studies including liver 
function tests, electrolytes, and creatinine were normal.  Her LDH was elevated at 446 with 
a negative direct Coombs test.  Her immunology workup showed normal immunoglobulin 
levels (IgG, IgA, IgM) and a largely unremarkable lymphocyte subsets with a slight increase 
in CD19+ B-cells and mild decrease in CD3+ T-cells).  Her molecular work up included 
sequencing analysis for JAK2, MPL, CALR and VPS45, all of which were negative.  
The patient has 3 full biological siblings ages 3-, 7- and 8- years old, all of which are 
reported to be healthy but could not be fully assessed given that they were in their home 
country at the time of evaluation at our center.  There is no family history of 
thrombocytopenia or anemia.  A now 27-year-old aunt on the maternal side was diagnosed 
with acute leukemia at age 8 years and has been in remission since.  
Family 4 
Patient 4-II-2 
Patient 4-II-2 is the second male child of consanguineous parents (first cousins) of Arabic 
decent from Algeria.  The boy was born full term via NSVD following an uneventful 
pregnancy.  He was seen at 18 months when a CBC revealed a severe microcytic anemia 
(5.1 g/dL) with low ferritin level (4ng/mL) and thrombocytopenia (96x109/L).  His anemia 
improved to 11.5 g/dL with hemoglobin F level (4%). He has a normal WBC of 6.44x109/L 
but a persistent severe thrombocytopenia with a platelet count between 10-30x109/L. The 
patient continued to be followed with supportive care and is now 25-years old at last follow 
up. He continues to have persistent thrombocytopenia with platelet counts under 10x109/L.  
He received IVIG and steroid therapy with no response, but has transient improvements in 
his platelet count after a platelet transfusion. The peripheral blood smear showed 
hypogranulated and gray platelets with a normal mean platelet volume.  The red cells 
showed microcytosis, anisiopoikylocytosis with leptocytes, spherocytes, dacrocytes and 
occasional Howell-Jolly bodies.  A partial deficiency in alpha granules in a subset of the 
platelets was confirmed by electronic microscopy.  The levels of platelet glycoproteins 
GPIb, GPIIbIIIa, GPIV studied by flow cytometry were normal.  The patient did not show any  
clinical bleeding.  He did have a cerebral cavernous malformation (cavernoma) but no other 
syndromic abnormalities. Two BM biopsies performed at 13 and 15 years of age were 
similar and showed erythroid dysplasia without blasts excess, dysmegakaryopoiesis with 
numerous hypobulated and small megakaryocytes.  Reticulin staining showed marked 
reticulin fibrosis (stage II). Additional investigations revealed normal BM cytogenetics and a 
normal diepoxybutane induced chromosomal breakage studies.  Molecular sequencing 
analysis was negative for mutations in WAS, GATA1, FOG, c-MPL, RUNX1, NBLEA2, 
TERC, TERT, TINF2 and DKC1.  The patient’s maternal grandfather deceased at the age 
of 65 of a myelodysplastic syndrome with blasts excess. 
Patient 4-II-3 
The proband’s (4-II-2) sister presented with thrombocytopenia in her first year of life but was 
not diagnosed until 11 years of age.  Her peripheral blood cell count showed leukocytosis 
(WBC 17 X109/L), a normal hemoglobin level (12.5 g/dL) with a normal hemoglobin F level, 
and mild thrombocytopenia with a platelet count of 97x109/L.  The patient continued to be 
followed and was 23-years old at the last follow up.  She had persistent mild to moderate 
thrombocytopenia with platelet counts between 80-140X109/L.  She has not had any 
bleeding symptoms despite three surgical procedures.  Her PB smear showed 
anisopoikylocytosis with target cells, rare schistocytes, leptocytes,  dacryocytes and 
occasional Howell-Jolly bodies.  The majority of her platelets showed a normal platelet 
volume (91%) with a small subset showing an increased platelet volume (9%). Some 
platelets showed decreased granulation (gray platelets, 8%).  Platelet function assays were 
normal.  A BM biopsy revealed a hypercellular marrow with dysmegakaryopoiesis and 
numerous micromegakaryocytes, moderate erythroid dysplasia without blast excess and 
normal granulopoiesis.  A marked reticulin fibrosis stage II was detected.  
  
 
Table S1
Genotype Observed 
frequency
Predicted
frequency
WT (+/+) 38 (26%) 37 (25%)
Het (+/hu) 72 (50%) 72 (50%)
Hom (hu/hu) 35 (24%) 36 (25%)
Data collected from 10 breeding pairs, average litter size 6 pups.
Table S2
Amplicon Primers (5’-3’)
MPIG6B LR_F ATCACAATCCCCTACAAAACAGG
MPIG6B LR_R1 GGAGAGGGATTATGGGGAGC
Sequencing Primers (5’-3’)
MPIG6B 1F GTTCTCCCCACGCCTAACTT
MPIG6B 1R ATCTTCCCACACACAACCCA
MPIG6B 2F GAAAGAGGAGACGGGATGGA
MPIG6B 2R CCTCCTCCGGGTATGTGTC
MPIG6B 3F CTGGCTGTCCCTCGTCAAA
MPIG6B 3R TTTTGCGAAGGTTCTGGTCC
MPIG6B 4_5F TGTCGGTGGGGTAGAGTCTA
MPIG6B 4_5R GGAGAGGGATTATGGGGAGC
G6b exon G6b untranslated region Human G6b exon Neighbouring gene
Mouse genomic region Vector knock-in region Vector region
Flippase recognition target
Oligo PCR primer target Start Start codon Stop Stop codon
Human genomic region
Figure S1
348 –
274 –
E
Figure S1
Figure S1. A constitutive knock-in strategy was used by Taconic to insert the human G6b
allele into (A) the genomic locus of mouse G6b. (B) A targeting vector containing human
G6b and a puromycin resistance cassette flanked by Flp recombinase sites was produced.
(C) The two homology arms of the targeting vector flanking the human gene provided sites
for homologous recombination to insert human G6b into the C57BL/6NTac embryonic stem
cell genome. (D) The puromycin resistance was removed by crossing mice expressing the
human G6b allele with a Flpe recombinase expressing mouse producing the final
constitutive knock-in allele. (E) Oligos 1 and 2 were used to distinguish WT and KI mice by
PCR.
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Figure S2. (A) mouse (m)G6b and human (h)G6b median fluorescence intensity
(MFI), mean ± SEM, n=6. (B) Representative density plots and mean ± SD of
percentage of events in each quadrant (n=6).2
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Figure S3. Relative proportions of Shp1 (blue) and Shp2 (red) expression in human
and mouse platelets. Numbers indicate copy number per platelet as measured by
quantitative proteomic studies (Burkhart et al, 2012 and Zeiler et al, 2014)
Figure S4. Distribution of transformed blood cell counts used for statistical analysis.
Platelet count, platelet volume, white blood cell (WBC) count and lymphocyte count data were
transformed using a modified Box-Cox power transformation and normality of distribution
verified using Browne-Forsythe test for equal variance. Transformed data were used for
analysis by one-way ANOVA and Dunnett’s post-hoc test to compare all genotypes to WT.
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Figure S5. Blood cell counts variation is independent of age in G6b KO mice. (A) Blood 
cell counts were plotted against age for G6b KO mice (n=37). (B) Regression analysis 
indicates that there is no correlation between age and hematological parameters.
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Figure S6
Figure S6. (A) Representative images of H&E and reticulin stained WT and G6bhu/hu
mouse spleens and femurs and quantification of megakaryocytes (MKs) in spleen and
femur sections (n=6). (B) Spleen to body weight ratio of indicated genotypes (n=3-
30). All data represented as mean ± SEM. Scale bar: 50 mm.
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Figure S7. Surface expression of the major platelet receptors in WT and G6bhu/hu
mice. All data represented as mean ± SEM.
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Figure S8. (A) Representative differential interference contrast (DIC) and Alexa-488-
conjugated phalloidin stained images of fibrinogen spread washed platelets (2 ×
107/mL) under both resting and 0.1 U/ml thrombin pre-activated conditions. (B)
Quantification of DIC images in indicated genotypes. Mean ± SEM, n=3.
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Figure S9. Normal signalling in fibrinogen adhered G6bhu/hu washed platelets (4 ×
108/mL).
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Figure S10. Mean aggregation and ATP release traces for WT and G6bhu/hu washed
platelets (2 × 108/mL) activated with indicated agonists. Area under the curve (AUC)
was compared for each of the traces (n=4-6, mean ± SEM, *** P<0.001).
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Figure S11.  Platelet flow adhesion morphological scoring representative images
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Figure S12. (A) Scatter plots of measured parameters of platelet adhesion and activation 
against platelet count in a cohort of WT mice with platelet counts ranging between 845-1745 × 
109/L (n=14-18). (B) R2 and P-values of linear regression models, demonstrating platelet count 
is not a good predictor of any of the parameters measured.
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Figure S13. Representative images and quantification of total platelet surface area
coverage, morphological score and JON/A-PE surface area coverage of heparin-
PPACK-fragmin anticoagulated whole blood flowed over collagen coated coverslips.
n=5-6, mean ± SEM, * P<0.05, ** P<0.01, *** P<0.001.
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Figure S14. (A) Quantification of mouse and human G6b-A total protein levels in
lysates prepared from washed platelets (4 × 108/mL). (B) Surface expression levels of
mouse and human G6b. (C) Surface expression levels of major platelet receptors.
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Figure S15.  Washed platelet spreading on fibrinogen scoring categories
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